查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1881453

乳癌診斷市場－全球產業規模、佔有率、趨勢、機會和預測，按類型、產品、應用、最終用途、地區和競爭格局分類，2020-2030年預測

Breast Cancer Diagnostics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type, By Product, By Application, By End-use, By Region, and By Competition, 2020-2030F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2024年全球乳癌診斷市場規模為629.8億美元，預計2030年將以11.21%的複合年成長率成長至1,191.4億美元。全球乳癌診斷市場涵蓋一系列用於檢測、鑑別和監測乳癌的專業檢測、影像檢查和活體組織切片程序。市場成長的主要促進因素包括全球乳癌發生率的不斷上升、公眾健康意識宣傳活動的加強以及政府為推廣早期檢測和篩檢計畫而採取的舉措。

市場概覽
預測期 2026-2030
2024年市場規模 629.8億美元
2030年市場規模 1191.4億美元
2025-2030年複合年成長率 11.21%
成長最快的細分市場 消耗品
最大的市場 北美洲

主要市場促進因素

主要市場挑戰

主要市場趨勢

目錄

第1章：產品概述

第2章：研究方法

第3章：執行概要

第4章：顧客之聲

第5章：全球乳癌診斷市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按類型（影像學檢查、活體組織切片、基因組檢測、血液檢測、其他）
    • 依產品類型（平台型產品、儀器型產品）
    • 按應用領域（篩檢、診斷和預測、預後、研究、其他）
    • 按最終用途（醫院和診所、診斷中心和醫學實驗室、其他）
    • 按地區
    • 按公司（2024 年）
  • 市場地圖

第6章：北美乳癌診斷市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國家分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲乳癌診斷市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國家分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區乳癌診斷市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲乳癌診斷市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東和非洲：國家分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲乳癌診斷市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國家分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章：市場動態

  • 促進要素
  • 挑戰

第12章：市場趨勢與發展

  • 併購（如有）
  • 產品發布（如有）
  • 最新進展

第13章：全球乳癌診斷市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商議價能力
  • 顧客的力量
  • 替代產品的威脅

第15章：競爭格局

  • Baxter Pharmaceuticals India Private Limited.
  • Bristol-Myers Squibb India Private Limited.
  • Cipla Ltd.
  • Roche Products (India) Private Limited.
  • Glenmark Pharmaceuticals Ltd.
  • Lupin Ltd
  • Abbott India Laboratories Limited
  • BIO-RAD LABORATORIES (INDIA) PRIVATE LIMITED.
  • Siemens Healthcare Private Limited.
  • Thermo Fisher Scientific India Private Limited.

第16章：策略建議

第17章調查會社について,免責事項

簡介目錄
Product Code: 21533

The Global Breast Cancer Diagnostics Market, valued at USD 62.98 Billion in 2024, is projected to experience a CAGR of 11.21% to reach USD 119.14 Billion by 2030. The Global Breast Cancer Diagnostics Market encompasses an array of specialized tests, imaging modalities, and biopsy procedures engineered to detect, characterize, and monitor breast cancer. Market growth is primarily driven by the escalating global incidence of breast cancer, augmented public health awareness campaigns, and governmental initiatives promoting early detection and screening programs.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 62.98 Billion
Market Size 2030USD 119.14 Billion
CAGR 2025-203011.21%
Fastest Growing SegmentConsumables
Largest MarketNorth America

Key Market Drivers

The increasing global incidence of breast cancer serves as a fundamental driver for the breast cancer diagnostics market. A rising number of new cases necessitates expanded screening and diagnostic capabilities worldwide to facilitate early detection and improve patient outcomes. This persistent disease burden creates consistent demand for diverse diagnostic solutions, from initial screening to definitive diagnosis and staging. For example, according to the American Cancer Society's Breast Cancer Facts & Figures 2024, an estimated 310,720 new cases of invasive breast cancer were expected to be diagnosed in the United States in 2024, underpinning the critical need for effective diagnostic tools. This widespread health challenge reinforces the market's expansion, with breast cancer being the most common cancer in women in 157 countries out of 185 in 2022, as reported by the World Health Organization in February 2024.

Key Market Challenges

The substantial cost associated with advanced diagnostic technologies represents a significant challenging factor impeding the growth of the Global Breast Cancer Diagnostics Market. These high expenses restrict accessibility to crucial screening and diagnostic procedures, particularly within developing economies where healthcare budgets are often constrained. This financial barrier limits the widespread adoption of comprehensive diagnostic screening protocols across various regions.

Key Market Trends

The growing adoption of liquid biopsy for early detection and monitoring represents a pivotal shift in breast cancer diagnostics. This non-invasive technique, which analyzes circulating tumor DNA or cells from a blood sample, offers a less burdensome alternative to traditional tissue biopsies, facilitating earlier detection and ongoing disease surveillance. Its utility is becoming increasingly recognized as research progresses, with clinical applications expanding beyond advanced disease. According to the American Society of Clinical Oncology, in January 2024, five liquid biopsy companion diagnostic assays were approved by the U. S. Food and Drug Administration for their clinical application in the diagnosis of cancer.

Key Market Players

  • Baxter Pharmaceuticals India Private Limited.
  • Bristol-Myers Squibb India Private Limited.
  • Cipla Ltd.
  • Roche Products (India) Private Limited.
  • Glenmark Pharmaceuticals Ltd.
  • Lupin Ltd
  • Abbott India Laboratories Limited
  • BIO-RAD LABORATORIES (INDIA) PRIVATE LIMITED.
  • Siemens Healthcare Private Limited.
  • Thermo Fisher Scientific India Private Limited.

Report Scope:

In this report, the Global Breast Cancer Diagnostics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Breast Cancer Diagnostics Market, By Type:

  • Imaging
  • Biopsy
  • Genomic Tests
  • Blood Tests
  • Others

Breast Cancer Diagnostics Market, By Product:

  • Platform-based Products
  • Instrument-based Products

Breast Cancer Diagnostics Market, By Application:

  • Screening
  • Diagnostic and Predictive
  • Prognostic
  • Research
  • Others

Breast Cancer Diagnostics Market, By End-use:

  • Hospitals & Clinics
  • Diagnostic Centers and Medical Laboratories
  • Others

Breast Cancer Diagnostics Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Breast Cancer Diagnostics Market.

Available Customizations:

Global Breast Cancer Diagnostics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Breast Cancer Diagnostics Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Type (Imaging, Biopsy, Genomic Tests, Blood Tests, Others)
    • 5.2.2. By Product (Platform-based Products, Instrument-based Products)
    • 5.2.3. By Application (Screening, Diagnostic and Predictive, Prognostic, Research, Others)
    • 5.2.4. By End-use (Hospitals & Clinics, Diagnostic Centers and Medical Laboratories, Others)
    • 5.2.5. By Region
    • 5.2.6. By Company (2024)
  • 5.3. Market Map

6. North America Breast Cancer Diagnostics Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Type
    • 6.2.2. By Product
    • 6.2.3. By Application
    • 6.2.4. By End-use
    • 6.2.5. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Breast Cancer Diagnostics Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Type
        • 6.3.1.2.2. By Product
        • 6.3.1.2.3. By Application
        • 6.3.1.2.4. By End-use
    • 6.3.2. Canada Breast Cancer Diagnostics Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Type
        • 6.3.2.2.2. By Product
        • 6.3.2.2.3. By Application
        • 6.3.2.2.4. By End-use
    • 6.3.3. Mexico Breast Cancer Diagnostics Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Type
        • 6.3.3.2.2. By Product
        • 6.3.3.2.3. By Application
        • 6.3.3.2.4. By End-use

7. Europe Breast Cancer Diagnostics Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type
    • 7.2.2. By Product
    • 7.2.3. By Application
    • 7.2.4. By End-use
    • 7.2.5. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Breast Cancer Diagnostics Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Type
        • 7.3.1.2.2. By Product
        • 7.3.1.2.3. By Application
        • 7.3.1.2.4. By End-use
    • 7.3.2. France Breast Cancer Diagnostics Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Type
        • 7.3.2.2.2. By Product
        • 7.3.2.2.3. By Application
        • 7.3.2.2.4. By End-use
    • 7.3.3. United Kingdom Breast Cancer Diagnostics Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Type
        • 7.3.3.2.2. By Product
        • 7.3.3.2.3. By Application
        • 7.3.3.2.4. By End-use
    • 7.3.4. Italy Breast Cancer Diagnostics Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Type
        • 7.3.4.2.2. By Product
        • 7.3.4.2.3. By Application
        • 7.3.4.2.4. By End-use
    • 7.3.5. Spain Breast Cancer Diagnostics Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Type
        • 7.3.5.2.2. By Product
        • 7.3.5.2.3. By Application
        • 7.3.5.2.4. By End-use

8. Asia Pacific Breast Cancer Diagnostics Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type
    • 8.2.2. By Product
    • 8.2.3. By Application
    • 8.2.4. By End-use
    • 8.2.5. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Breast Cancer Diagnostics Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Type
        • 8.3.1.2.2. By Product
        • 8.3.1.2.3. By Application
        • 8.3.1.2.4. By End-use
    • 8.3.2. India Breast Cancer Diagnostics Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Type
        • 8.3.2.2.2. By Product
        • 8.3.2.2.3. By Application
        • 8.3.2.2.4. By End-use
    • 8.3.3. Japan Breast Cancer Diagnostics Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Type
        • 8.3.3.2.2. By Product
        • 8.3.3.2.3. By Application
        • 8.3.3.2.4. By End-use
    • 8.3.4. South Korea Breast Cancer Diagnostics Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Type
        • 8.3.4.2.2. By Product
        • 8.3.4.2.3. By Application
        • 8.3.4.2.4. By End-use
    • 8.3.5. Australia Breast Cancer Diagnostics Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Type
        • 8.3.5.2.2. By Product
        • 8.3.5.2.3. By Application
        • 8.3.5.2.4. By End-use

9. Middle East & Africa Breast Cancer Diagnostics Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type
    • 9.2.2. By Product
    • 9.2.3. By Application
    • 9.2.4. By End-use
    • 9.2.5. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Breast Cancer Diagnostics Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Type
        • 9.3.1.2.2. By Product
        • 9.3.1.2.3. By Application
        • 9.3.1.2.4. By End-use
    • 9.3.2. UAE Breast Cancer Diagnostics Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Type
        • 9.3.2.2.2. By Product
        • 9.3.2.2.3. By Application
        • 9.3.2.2.4. By End-use
    • 9.3.3. South Africa Breast Cancer Diagnostics Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Type
        • 9.3.3.2.2. By Product
        • 9.3.3.2.3. By Application
        • 9.3.3.2.4. By End-use

10. South America Breast Cancer Diagnostics Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Type
    • 10.2.2. By Product
    • 10.2.3. By Application
    • 10.2.4. By End-use
    • 10.2.5. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Breast Cancer Diagnostics Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Type
        • 10.3.1.2.2. By Product
        • 10.3.1.2.3. By Application
        • 10.3.1.2.4. By End-use
    • 10.3.2. Colombia Breast Cancer Diagnostics Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Type
        • 10.3.2.2.2. By Product
        • 10.3.2.2.3. By Application
        • 10.3.2.2.4. By End-use
    • 10.3.3. Argentina Breast Cancer Diagnostics Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Type
        • 10.3.3.2.2. By Product
        • 10.3.3.2.3. By Application
        • 10.3.3.2.4. By End-use

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Breast Cancer Diagnostics Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Baxter Pharmaceuticals India Private Limited.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Bristol-Myers Squibb India Private Limited.
  • 15.3. Cipla Ltd.
  • 15.4. Roche Products (India) Private Limited.
  • 15.5. Glenmark Pharmaceuticals Ltd.
  • 15.6. Lupin Ltd
  • 15.7. Abbott India Laboratories Limited
  • 15.8. BIO-RAD LABORATORIES (INDIA) PRIVATE LIMITED.
  • 15.9. Siemens Healthcare Private Limited.
  • 15.10. Thermo Fisher Scientific India Private Limited.

16. Strategic Recommendations

17. About Us & Disclaimer